Anti-atherogenic and anti-ischemic potentials of Croton membranaceus observed during sub-chronic toxicity studies

BACKGROUND: Croton membranaceus (CM) is used for benign prostate hyperplasia treatment. OBJECTIVE: Sub-chronic toxicity studies are non-existent and provided the basis for this study. MATERIALS AND METHODS: 90 days oral administration of a low dose (LD) (30 mg/kg b. wt.), medium dose (MD) (150 mg/kg...

Descripción completa

Detalles Bibliográficos
Autores principales: Afriyie, Dan K., Asare, George A., Bugyei, Kwasi, Asiedu-Gyekye, Isaac, Gyan, Ben A., Adjei, Samuel, Addo, Phyllis, Sittie, Archibald, Nyarko, Alexander K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579014/
https://www.ncbi.nlm.nih.gov/pubmed/23598919
http://dx.doi.org/10.4103/0974-8490.105640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579014/
https://www.ncbi.nlm.nih.gov/pubmed/23598919
http://dx.doi.org/10.4103/0974-8490.105640

Ejemplares similares